Edition:
India

Celon Pharma SA (CLNP.WA)

CLNP.WA on Warsaw Stock Exchange

41.50PLN
23 Sep 2020
Change (% chg)

-0.85zł (-2.01%)
Prev Close
42.35zł
Open
42.00zł
Day's High
42.35zł
Day's Low
41.15zł
Volume
17,052
Avg. Vol
26,009
52-wk High
50.40zł
52-wk Low
23.05zł

Latest Key Developments (Source: Significant Developments)

Celon Pharma Files To Begin Clinical Trial Of CPL 409116
Wednesday, 16 Sep 2020 

Sept 16 (Reuters) - Celon Pharma SA ::HAS APPLIED TO POLAND'S MEDICINES AUTHORITY FOR CONSENT TO START FIRST PHASE OF CLINICAL TRIAL OF INHIBITOR JAK/ROCK - CPL 409116.CPL 409116 IS INHIBITOR DEVELOPED IN AUTOIMMUNE INDICATIONS.  Full Article

Celon Pharma Signs Settlement With GlaxoSmithKline Units And Glenmark Group On Sales Of Salmex Drug
Monday, 13 Jan 2020 

Jan 13 (Reuters) - Celon Pharma SA ::SAYS SIGNS SETTLEMENT WITH GLAXOSMITHKLINE UNITS AND GLENMARK GROUP REGARDING SALES OF SALMEX DRUG IN POLAND AND SELECTED EUROPEAN MARKETS.SAYS UNDER SETTLEMENT PARTIES WITHDRAW FROM LAWSUITS REGARDING SALES OF SAID DRUG IN POLAND AND EUROPEAN MARKETS.SAYS UNDER SETTLEMENT CO AND GLENMARK TO SELL SALMEX DRUG IN POLAND AND IN SELECTED EUROPEAN MARKETS WITHOUT RISK OF VIOLATING INTELLECTUAL PROPERTY RIGHTS.  Full Article

Celon Pharma Says Receives Patent From Japanese Patent Office Regarding Inhibitory FGFR
Monday, 23 Sep 2019 

Sept 23 (Reuters) - Celon Pharma SA ::SAYS RECEIVES PATENT FROM JAPANESE PATENT OFFICE REGARDING INHIBITORY FGFR AND ITS USE IN ONCOLOGICAL TREATMENTS AND MEDICINAL PRODUCTS.  Full Article

Celon Pharma Plans FY 2018 Dividend Of 0.24 Zloty/Shr
Friday, 22 Mar 2019 

March 22 (Reuters) - Celon Pharma SA ::MANAGEMENT RECOMMENDS FY 2018 DIVIDEND OF 0.24 ZLOTYPER SHARE.  Full Article

Celon Pharma Gets Patent For PDE10A Inhibitors In China
Friday, 8 Mar 2019 

March 8 (Reuters) - Celon Pharma SA ::SAID ON THURSDAY IT HAS BEEN GRANTED PATENT FOR PHOSPHODIESTERASE 10A INHIBITORS (PDE10A) BY CHINA NATIONAL INTELLECTUAL PROPERTY ADMINISTRATION (CNIPA).DEVELOPMENT OF THE INHIBITOR IN PATIENTS SUFFERING FROM PSYCHOTIC DISORDERS, INCLUDING SCHIZOPHRENIA, IS IMPLEMENTED UNDER NOTESZHD PROJECT IN THE STRATEGMED PROGRAM.THE PROJECT IS IN PHASE I OF CLINICAL TRIALS.  Full Article